SCHEMBL25692191

SCHEMBL25692191

CSN(C)c1ccccc1Nc1nc(Nc2ccc(C(=O)O)cc2)ncc1C(F)(F)F

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 2/20 0.69
GSK3B P49841 2/20 0.69
PTK2 Q05397 10/20 0.59
JAK2 O60674 2/20 0.59
NTRK1 P04629 1/20 0.59
TYK2 P29597 1/20 0.59
KDR P35968 1/20 0.59
JAK3 P52333 1/20 0.59
PTK2B Q14289 1/20 0.59
NTRK3 Q16288 1/20 0.59
NTRK2 Q16620 1/20 0.59
CDC7 O00311 1/20 0.56
ROCK2 O75116 1/20 0.56
MAP4K4 O95819 1/20 0.56
PIM1 P11309 1/20 0.56
PRKACA P17612 1/20 0.56
CDK7 P50613 1/20 0.56
CDK9 P50750 1/20 0.56
HIPK2 Q9H2X6 1/20 0.56
IRAK4 Q9NWZ3 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30471334 0.87 GSK3A (0.67) GSK3AGSK3BPTK2JAK2NTRK1
SCHEMBL25692194 0.87 GSK3A (0.67) GSK3AGSK3BPTK2JAK2NTRK1
SCHEMBL25692152 0.87 CDC7 (0.52) GSK3AGSK3BPTK2JAK2NTRK1
SCHEMBL25692573 0.86 AURKA (0.70) GSK3AGSK3BPTK2JAK2JAK3
SCHEMBL25692215 0.85 PTK2 (0.58) PTK2JAK2NTRK1TYK2KDR
SCHEMBL25692208 0.82 HDAC6 (0.56) GSK3AGSK3BPTK2JAK2NTRK1
SCHEMBL24752993 0.82 GSK3A (0.73) GSK3AGSK3BPTK2JAK2NTRK1
SCHEMBL24752211 0.81 GSK3A (0.72) GSK3AGSK3BPTK2JAK2NTRK1
SCHEMBL25692349 0.80 AURKA (0.52) GSK3AGSK3BJAK2NTRK2CDC7
SCHEMBL24752409 0.79 GSK3A (0.68) GSK3AGSK3BPTK2JAK2NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023121251-A1 EGFR AND HDAC DUAL INHIBITOR COMPOUNDS AND MEDICAL USE THEREOF 한국원자력의학원 2023-06-29 WO disclosed